Oral vs. Injectable Semaglutide: Comparing Effects on Liver Inflammation and Oxidative Stress
Both oral and injectable semaglutide improved liver inflammation and fibrosis markers in diabetic patients with fatty liver disease, with first-ever data on oxidative stress reduction.
Quick Facts
What This Study Found
Both oral and injectable semaglutide reduced liver inflammation, fibrosis markers, and oxidative stress in T2D patients with MASLD — the first oxidative stress data for semaglutide.
Key Numbers
60 T2D + MASLD patients. 2:1 ratio injectable to oral. 6-month follow-up. Measured transient elastography (CAP), liver enzymes, cytokines, and peroxidation products.
How They Did This
Real-life, open-label, prospective study comparing standard doses of injectable vs. oral semaglutide in T2D patients with liver steatosis, measuring liver and systemic inflammation, fibrosis, and oxidative stress markers.
Why This Research Matters
Fatty liver disease is increasingly common and can progress to cirrhosis. Showing that both semaglutide formulations reduce oxidative stress adds a new dimension to its liver-protective effects.
The Bigger Picture
This study strengthens the case for semaglutide as a comprehensive metabolic therapy that addresses not just blood sugar and weight but also the liver inflammation and oxidative damage driving fatty liver disease progression.
What This Study Doesn't Tell Us
Open-label design without blinding. Real-life study without randomization to formulations. Small sample size not specified in abstract.
Questions This Raises
- ?Are there clinically meaningful differences between oral and injectable semaglutide for liver protection?
- ?Does oxidative stress reduction persist with long-term semaglutide use?
Trust & Context
- Key Stat:
- First oxidative stress data Both oral and injectable semaglutide reduced oxidative stress markers in fatty liver patients — previously unreported
- Evidence Grade:
- Open-label, prospective, real-world study. Provides useful comparative data between formulations but lacks the rigor of a blinded randomized trial.
- Study Age:
- Published in 2025, providing the first head-to-head comparison of semaglutide formulations for liver outcomes.
- Original Title:
- Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.
- Published In:
- Acta diabetologica, 62(9), 1429-1437 (2025)
- Authors:
- Petralli, Giovanni, Zoppo, Alice Del, Rovera, Chiara, Raggi, Francesco, Salvati, Antonio, Moriconi, Diego, Distaso, Mariarosaria, Brunetto, Maurizia Rossana, Solini, Anna
- Database ID:
- RPEP-13037
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Is oral semaglutide as good as injectable for fatty liver?
This study suggests both formulations improve liver inflammation, fibrosis, and oxidative stress markers. The injectable may have a slight advantage, but oral semaglutide still provided meaningful liver benefits.
What is oxidative stress and why does it matter for liver disease?
Oxidative stress occurs when harmful reactive molecules damage cells. In fatty liver disease, oxidative stress drives progression from simple fat accumulation to inflammation, fibrosis, and eventually cirrhosis. Reducing it could slow disease progression.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13037APA
Petralli, Giovanni; Zoppo, Alice Del; Rovera, Chiara; Raggi, Francesco; Salvati, Antonio; Moriconi, Diego; Distaso, Mariarosaria; Brunetto, Maurizia Rossana; Solini, Anna. (2025). Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.. Acta diabetologica, 62(9), 1429-1437. https://doi.org/10.1007/s00592-025-02466-7
MLA
Petralli, Giovanni, et al. "Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.." Acta diabetologica, 2025. https://doi.org/10.1007/s00592-025-02466-7
RethinkPeptides
RethinkPeptides Research Database. "Different formulations of semaglutide and oxidative stress i..." RPEP-13037. Retrieved from https://rethinkpeptides.com/research/petralli-2025-different-formulations-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.